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Introduction 
Menopause, a healthy and normal life occurrence among women ages 40-58, is often 
considered a medical “condition” and is treated as a nuisance. Symptoms of the change can 
range from hot flashes and vaginal discomfort to fatigue and general irritability.  Women more 
recently have been turning away from the traditional Hormone Replacement Therapy (HRT) in 
favor of more “natural” alternatives, such as meditation, acupuncture, vitamins, and 
supplements (Menopause Practice, a Clinician’s guide, 2004).  In particular these supplements 
are viewed as safe alternatives to HRT because they contain phytoestrogens, which are plant 
based and so viewed as “natural.” 
There are several different forms of estrogen, but the strongest and most prominent in humans 
is 17β-estradiol.  Estrogens are primarily made in the ovaries, specifically they are believed to 
be produced in the egg follicle and interstitial cells, but can be secreted by the adrenal glands as 
well (Estrogen, Encyc. Britannica).  While estrogens interact as a complex system with other 
signaling hormones, they primarily affect areas normally associated with reproduction.  Among 
roles such as controlling the development of egg follicles, thickening the vaginal wall, and 
uterine contractions, estrogen also contributes largely to the general development of the 
female body.  Figure 1 shows a chart denoting the major areas in which estrogen plays a role.   
   
Figure 1: Diagram of the female body denoting major areas estrogen affects.(Understanding 
Cancer Series, Natl. Cancer. Inst.) 
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Estrogen is a steroidal molecule, and like other steroids is derived from cholesterol.  The 
structure of estrogen can be seen in Figure 2.  Estrogen receptors (ERs) belong to the nuclear 
receptor family; receptors of this type are ligand induced transcription factors.  There are two 
types of estrogen receptors, α-ER and β-ER.  The receptors have a different distribution 
throughout the body, which possibly indicates they have different functions. This distribution 
can be seen in Figure 3.  It has been determined that both types of receptors reside within the 
nucleus of the cell, where estrogen reaches them through passive diffusion through the 
membrane.  However due to the fact that the receptors can only be studied in disrupted cells, it 
cannot be determined exactly where the receptors lie (Creighton, Thomas C. 1999).  
 
 
Figure 2: Molecular structure of estradiol(Gangolli, 
2005) 
 
 
                                                                  
 
 
 
Figure 3: Locations of α and β estrogen 
receptors in the human body(Estrogen 
Receptors and Functions, Carnegie melon) 
 
 
 
 
The structure of both receptors is divided into 6 functional domains.  Overall there is a 44% 
amino acid consensus between the two types of receptors.  The A/B domain contains the 
Activation Function 1 (AF-1) sequence.  AF-1 binds coactivators such as growth factors.  The C 
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domain is 88% conserved between the α-ER and β-ER, and contains the DNA binding domain.  
The D region, commonly referred to as the hinge region, links the domains together. The E/F 
domain is responsible for dimerization, and also contains both the ligand binding site and the 
AF-2 site.  The AF-2 site interacts with a sequence known as the nuclear receptor interaction 
domain, or NR region on coactivators.  The sequence of this region is LXXLL, where L is leucine 
and X is any amino acid (Estrogen Receptors and Functions, Carnegie Melon).  The significant 
differences in amino acid sequences of the AF sites and ligand binding sites between the two 
types of receptors leaves the possibility of different coactivator interactions. 
The mechanism of ligand binding to the estrogen receptor is sometimes referred to as the 
“mousetrap model.” The secondary structure of the receptor consists of 12 alpha helixes, and 
the tertiary structure has the helixes organized to create a hydrophobic pocket for the polar 
ligand (estrogen) to bind. When the ligand binds, an allosteric change forces helix 12 to close 
over the pocket and “trap” the ligand inside the hydrophobic region.  This movement causes a 
hydrophobic groove to be created on the surface of the receptor, and allows the NR region of 
coactivators to bind.  This optimal position of helix 12 is known as the agonist position 
(Creighton, Thomas C. 1999). 
The receptor can bind nearly any molecule with an aromatic ring structure.  This is due 
predominantly to the large size of the hydrophobic cavity—it is nearly twice that of the volume 
of 17β-estradiol (Brzozowski et al., 1997).  Some molecules prevent helix 12 from trapping the 
ligand, and instead cause the helix to lie in a hydrophobic grooved formed by helix 3 and 5.  This 
does not properly display the AF-2 region of the receptor, and very little if any coactivators can 
bind.  Molecules such as this are known as estrogen receptor modulators (SERMS) and are 
thought to play an important role in regulation of receptor activity.  The complimentarity 
between helix 12 and the hydrophobic groove that is formed indicates that the antagonist 
position is not just an intermediate or accidental conformation(Brzozowski et al., 1997). 
Molecules that bind the receptors in the agonist conformation stimulate transcription of 
estrogen regulated genes, while those that bind in the antagonist position inhibit their 
transcription.  The receptors bind DNA as homo dimers at sites known as estrogen response 
elements (EREs) with the consensus sequence  5’GGTCAnnnTGACC-3’, where n is any 
nucleotide (Paech et al.1997).  The EREs are very sensitive and the receptor binding is very 
specific, as there is only a 2 nucleotide difference between EREs and the hormone response 
elements for glucocorticoid, progesterone, and androgen receptors (Creighton, Thomas C. 
1999).  The binding of the receptor to the EREs directly stimulates transcription of the gene by 
recruiting the necessary proteins required to start the process. 
As females reach the age of menopause their ovaries slow the production of estradiol, and the 
primary hormone in the body becomes estrone.  Estrone has a lower affinity for receptors, so is 
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viewed as a weaker estrogen.  This switch is what creates so many symptoms of discomfort for 
menopausal women (Menopause Online).  Hormone replacement therapy eases much of the 
discomfort of the switch by replenishing women’s supplies of estradiol.   
HRT works by supplementing the female body’s decreasing supply of hormones with either 
estradiol or an estradiol and progesterone combination.  HRT was practiced widely until recent 
studies showed numerous adverse effects directly resulting from HRT.  For example, even 
though the risk for colorectal cancer and bone fractures were markedly decreased in women 
who used the therapy, there were increases in risk of breast cancer, stroke, heart attack and 
blood clots (US. Dept. of Health and Human Services, 2005).   
The reason behind the increased risk of cancers surrounding the use of HRT is related to the 
primary function of estrogen to increase cell proliferation.  Tissues that have increased 
proliferation due to estrogen are breast and uterine; consequently breast and uterine cancer 
are the most common cancers resulting from HRT.  Although estrogen does not directly cause 
cancer, it greatly increases the chances of anyone with DNA mutations in estrogen responsive 
tissues of developing cancer(Natl. Cancer Inst.).  Many cancers are also estrogen responsive, 
which means HRT would increase the proliferation rate of cancer already in existence. 
Phytoestrogens are not produced in the human body, but will still bind to estrogen receptors, 
just at a lower affinity than does estrogen. While there is anecdotal evidence that attest 
products alleviate the symptoms associated with menopause, there is little research on their 
effects on cell proliferation. To address this question, Caron (2007) investigated the effects of 
Promensil, an over the counter supplement made up of phytoestrogens and marketed  as an 
alternative to HRT, on the proliferation of MCF-7 cells.   MCF-7 (ATCC# HTB-22) is an estrogen 
responsive breast epithelial cell line that has been used as a model system to study estrogen 
responsiveness for many years (Berthois et al. 1986).  While Caron’s work suggested that 
Promensil decreases the growth rate of MCF 7 cells and increases the expression of caspase-3, 
an apoptosis related protein, the MCF7 cells used in the study appeared to be minimally or non 
responsive to estrogen. 
Hamelers et al. in 2003 investigated the variable response of various strains of MCF-7 cells to 
estrogen.  They suggested that insulin-like growth factor 1(IGF 1) increases the estrogen 
responsiveness of MCF-7 cells.  This may also explain increasing estrogen responsiveness at 
higher passage numbers, due to  selection for cells that have a growth advantage as a result of 
endogenous production of IGF for autocrine signalling.  
Research presented here attempts to restore estrogen responsiveness to the MCF-7 cells used 
by Caron.  This is necessary to validate the results of the original study suggesting that certain 
phytoestrogens may actually have a protective role in the development of breast cancer.   In 
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order to determine the best conditions for estrogen responsiveness, effects of both the passage 
number and addition of IGF have been explored in this study. 
 
Materials and Methods 
Culture Conditions  
MCF7 cells were maintained in either T-25 or T-75 flasks. They were incubated at 37°C, 5% CO2 
and grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS).  Cells were given fresh media every 3 days, and split when at least 80% confluent. 
Passaging  
Cells were passaged using trypsin EDTA (2.5mg/l Trypsin, 0.2g/l EDTA)minutes until loosened 
enough to be resuspended.  They were then resuspended in DMEM with 10% FBS and split into 
2 or more T-25 (or T-75) flasks in fresh media.  Cells were used either from a fresh split, or from 
a stock frozen in medium containing 10% FBS and 10% DMSO. 
Estradiol Treatment 
Cell concentrations were determined via hemocytometer counts and plated at an average cell 
count of 3x105 cells/ml.  
 A 1:2 dilution series of β-estradiol in 100% ethanol at starting concentration 1x10-7[M] was 
prepared.  The dilutions were as follows:2x10-5, 1x10
-5, 5x10-6, 2.5x10-7, and 1.25-6[M]. For 
treatment of cells, 5µl of the appropriate solutions were added to the wells.   
Cells were plated in 1ml of phenol red free DMEM supplemented with 10% DCC/charcoal 
stripped FBS in either 6, 12 or 24 well plates.  12 hours after plating, estradiol was added to the 
cells as shown in Tables 1, 2, and 3.  As controls cells were plated both with and without 0.5% 
ethanol (5µl of 100% ethanol).  24 hours after estradiol treatment cells were frozen for 
immunoblotting or used in an MTS assay of cell proliferation. 
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Table 1: Estradiol Treatment For a 12 well plate. Concentrations of estradiol indicate final 
concentration present in 1ml media containing cells. The well containing only media is to serve 
as a blank for the MTS assay. 
 1 2 3 4 
A 3x105cells 3x105cells 3x105cells,5µl 100% 
ethanol 
1ml media 
B 3x105cells, 
1x10-7M estradiol 
3x105cells, 
5x10-8 M estradiol 
3x105cells, 
2.5x10-8 M estradiol 
3x105cells, 
1.25x10-9M estradiol 
C 3x105cells,1x10-7M 
estradiol 
3x105cells,5x10-8 M 
estradiol 
3x105cells, 2.5x10-8 M 
estradiol 
3x105cells, 1.25x10-9M 
estradiol 
 
 
 
Table 2: Estradiol Treatment For a 24 well plate Concentrations of estradiol indicate final 
concentration present in 1ml media containing cells. The well containing only media is to serve 
as a blank for the MTS assay. 
 1 2 3 4 5 6 
A 1ml media 3x105cells, 
1x10-7M 
estradiol 
3x105cells, 
5x10-8  M 
estradiol 
1ml cells, 
2.5x10-8 M 
estradiol 
3x105cells,  
1.25x10-9 M 
estradiol 
3x105cells, 
6.25-9 M 
estradiol 
B 3x105cells, 
5µl 100% 
ethanol 
3x105cells, 
1x10-7M 
estradiol 
3x105cells, 
5x10-8  M 
estradiol 
1ml cells, 
2.5x10-8 M 
estradiol 
3x105cells,  
1.25x10-9 M 
estradiol 
3x105cells, 
6.25-9 M 
estradiol 
C 3x105cells 3x105cells, 
1x10-7M 
estradiol 
3x105cells, 
5x10-8  M 
estradiol 
1ml cells, 
2.5x10-8 M 
estradiol 
3x105cells,  
1.25x10-9 M 
estradiol 
3x105cells, 
6.25-9 M 
estradiol 
D 3x105cells 3x105cells, 
1x10-7M 
estradiol 
3x105cells, 
5x10-8  M 
estradiol 
1ml cells, 
2.5x10-8 M 
estradiol 
3x105cells,  
1.25x10-9 M 
estradiol 
3x105cells, 
6.25-9 M 
estradiol 
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Table 3: Estradiol Treatment For a 6 well plate 
 1 2 3 
A 1ml cells, 5µl 100% ethanol 
3x105cells, 5µl 1x10-7M 
estrogen 
3x105cells, 5µl 5x10-8 M 
estrogen 
B 
3x105cells, 5µl 2.5x10-8 M 
estrogen 
3x105cells, 5µl  1.25x10-9 M 
estrogen 
3x105cells, 5µl 6.25-9M 
estrogen 
 
IGF Treatment  
Cells grown with IGF were plated in the same manner except they were exposed to 
concentrations of 2ng/ml IGF-1(Sigma, St. Louis, MO) at the same time as the estrogen 
treatments.  For IGF-1 studies, cells from multiple passages were plated on a single plate and 
treated with IGF-1 simultaneously. 
MTS Assay   
 
The Cell Titer96© AQueous Non-Radioactive Cell Proliferation Assay was purchased from 
Promega.  The assay contains a tetrazolium compound MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and an electron coupling 
reagent PMS (phenazine methosulfate).  The MTS is converted by the dehydrogenase enzymes 
found in metabolically active cells into formazan, a substance soluble in culture media.  The 
absorbance of the cultures is then read at 490 nm and is directly proportional to the amount of 
metabolic activity of the cells—hence it should be an accurate measure of cell 
viability(Technical Bulletin, Promega 2007). 
 
To perform the MTS assay 20µl of the MTS solution was added to each well of the plates (either 
the 12 or 24 well plates) and incubated at 37°C for approximately 2 ½ hours. This occurred 24 
hours after the estradiol treatment. The plates were then read in the plate reader at 490 nm 
and absorption values taken, and the average reading of data was taken for plates with only 
one passage number.   
Immunoblotting  
To prepare the cells for immunoblotting, the plates were rinsed in PBS (10mM sodium 
phosphate, 150mM NaCl, pH 7.4) and frozen at -80°C.  The plates were then scraped in 100µl 
cold PBS and a Bradford Assay was performed.  In this manner the total protein concentrations 
could be normalized among samples. 
P a g e  | 8 
 
A standard SDS-PAGE was run with pre-cast Pierce Precise Protein 10 well 12% gels for 
approximately 40 minutes at 250 Volts in running buffer (100 mM Tris, 100 mM HEPES, 1% SDS, 
pH 8.0).  The proteins were then transferred to a MilliporePVDF membrane using semi-dry 
blotting technique which involved wetting the membrane with methanol then using a semi-dry 
transfer buffer (25mM Tris, 250 mM glycine, 15% methanol) and running the blotting apparatus 
at 20 Volts for 30 minutes.  The membrane was then blocked in 5% non-fat dry milk in PBS for 
10 minutes, then washed in TBS (10mM Tris HCL, 150 mM NaCl, pH 7.4).  The membrane was 
incubated in PCNA mouse antibody (purchased from Santa Cruz Biotechnology, used at a 1:200 
dilution) overnight at 4°C, then washed for at least 10 minutes each in TBS, TBS+ 10% Tween, 
and TBS again.  Goat anti-mouse (purchased from Santa Cruz Biotechnology, used at 1:1500 
dilution) was incubated on the membrane overnight at 4°C. The membrane was washed for at 
least 10 minutes each in TBS, TBS+ 10% Tween, and TBS, and was developed using 
NBT/BCIP+Tetramisol.   
Results 
Figure 4 shows the proliferation effects of estrogen on cells at different  passage number as 
determined by the MTS assay   While there is some indication that the cells at lower passage 
numbers had fewer cells, the pattern is not consistent across passage number.  Additionally, there 
is no clear change in cell number with increasing estrogen concentration across the range tested.  
 
 Figure  4. Effects of estrogen on proliferation for cells from different passage numbers.  
were cultured as decscribed and treated with estrogen.  24 hours later, 
determined at Å490 using an MTS assay. 
replicate samples..   
 
Figure 5 shows the effects as determined by the MTS assay of estrogen addition on cells at 
different  passage number treated  with IGF. (Data for Figures 4 and 5 can be found in 
Appendix as Tables 1-6)  Again, there is no clear pattern
concentration range tested .  However, unlike in Figure 5, there is no indication of differences in 
cell number that correlate with passage number. 
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Cells 
 Figure  5. Effects of estrogen on proliferation for cells from different passage numbers 
treated with X M IGF-1.  Cells were cultured as described and treated with estrogen and IGF.  24 
hours later, cell number was determined
represents a  single sample.   
 
 
Figure 6 shows the PCNA immunoblot results for passage 13 cells grown in the presence of  
IGF-1 and estradiol treated (Data from the Bradford Assay used to normalize loading is shown in 
the Appendix, Table 7).  For all of the cells treated with estrogen at varying concentrations, the 
level of PCNA is increased over the untreated control.  However, the intensity of the band does 
not increase in relation to estrogen concentration across the range tested.
seems greatest at the lowest concentration of estrogen, and appears to decrease somewhat as 
estrogen concentration increases. 
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Figure 3: Passage 13 Immunoblot   Cells were cultured as described in the presence of X M IGF
and treated with  estrogen at the indicated concentrations
an anti-PCNA antibody. 
 
Figure 4 shows that there is no obvious correlation between the estrogen concentrations and 
proliferation without the addition of IGF.  There is a slight relationship between the passage 
numbers and the viable cell number however.  As can be seen, passage numbers 
fewer cells at all concentrations of estrogen than cells from higher passage numbers.  Since all 
the cells were seeded at approximately the same density, this may be a reflection of increased 
growth rate at increased passage number as reporte
seeing such a higher density of cells at higher passage numbers 
passage numbers have selected for cells that produce their own IGF.  
With the addition of IGF, there still appears to be n
amounts and proliferation or passage num
passage number has even less of an effect on the overall proliferation, which does support the 
theory that IGF differs between higher and lower passage numbers. If the amount of IGF added 
helps to normalize the relative amounts of IGF present between passage numbers, then of 
course there would not be a major difference. As for the effects of estrogen, there appears to 
be no general correlation in any of the passage numbers
maximal across the concentration range used. 
Another possibility is that the plate reader was not accurate.  The plate reader was set 
indefinitely to read  96 well plates, so in
from the MTS assay had to be transferred into 96 well plates.  The 12 well plates fit in the 
reader, but the placement of the 96 well
P a g e
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Lane 6 0M estrogen  
.  Immunoblotting was carried out using 
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and was probably not very accurate at all.  In addition, repeat trials of the same plates read 
resulted in erratic results, when no change had been made except for the passing of several 
seconds.  Visual evidence suggests the MTS assay worked perfectly, but given the inadequacies 
of the plate reader it is safe to say the error lies there. 
In the immunoblot(Figure 6) there appears to be some correlation to the amount of estrogen 
added.  Lane 6 contains no estrogen and shows the weakest band, this is consistent with 
expected results.  There appears to be a general darkening of bands with decreasing amounts 
of estrogen, except for in lane 2.  It is possible this shows the beginnings of a relationship, but 
more data needs to be collected before any conclusions can be drawn.  
It has been shown that phenol red is structurally similar to estrogen.  Although the binding 
capacity of phenol red to the estrogen receptor is 0.001% that of estradiol’s, the concentration 
of phenol red  in DMEM medium is 45µM, which is far more concentrated than the amounts of 
estrogen added (Berthois et al. 1986). It is possible that the prolonged periods in phenol red 
containing media prior to experimental conditions contributed to the lack of an effect.  Perhaps 
the increased IGF, in addition to the prolonged period spend in phenol red containing media 
both contributed to the increase in growth rate of higher passage cells.  It was also observed 
that cells at higher passage number  reached confluence faster than those from lower passage 
number, and this is in keeping with the findings. 
Future Experiments 
With the current risk of cancer caused by HRT, it is imperative that more studies be done to 
confirm that phytoestrogens do inhibit proliferation.  In order to confirm previous findings 
specific to the strain of MCF-7 cells used, they must be shown to have the characteristic 
response to estrogen.  This could most likely be done by repeating the previous experiments 
but using phenol red free media and DCC/charcoal stripped FBS for the entire course of cell 
culture.  If that proves to be too impractical, then they could be grown in those conditions for 
only several days.  If this fails to work, then growing cells in hormone and phenol red free, but 
with the addition of 2 ng of IGF may induce estrogen responsiveness of the cells.  Most likely 
the MTS assay will prove to be unreliable and it would probably be more efficient to rely on 
immunoblotting for PCNA as a measurement of cell proliferation.  In addition to the change in 
growing conditions, perhaps future experiments could include a broader range of estrogen 
concentrations.  This could help make any minor differences in responses more apparent. 
If the desired response of the MCF-7 cell line is unable to be achieved, then it may be 
worthwhile to repeat the entire experiment starting with the effects of Promensil on a different 
estrogen responsive breast epithelial cell line.  There are a wide variety of cell lines available 
from the ATCC that would be suited to this experiment.  Even if the MCF-7 line does prove to be 
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estrogen responsive, it would eventually be productive to investigate alternative lines to search 
for a general trend. 
Genistein is the active and most prominent ingredient of Promensil, according to the producers; 
however it was found to contain a number of unidentified substances.  In order to fully 
understand the effects Promensil has on MCF7 cells, the components must be studied both 
individually and in different combinations.  This would lead to a myriad of experiments, given 
the large variety of components that make up the supplement.  Ideally the exact components 
that induce apoptosis in the cells should be isolated for further study. 
This study has so far focused on only one of the many supplements available over the counter.  
In the future it would be valuable to broaden the horizon to other brands.  Most likely the 
proportions of phytoestrogens in different brands are different; it would be interesting to see a 
correlation between these differences and the effects on cell proliferation. 
The effects of having different proportions of both 17β-estradiol and Promensil present should 
be studied.  In no instance is 17β-estradiol entirely non-existent in the body, so experiments in 
vivo should reflect this.  Eventually it would also be important to investigate the effects of 
estrone combined with Promensil, since estrone becomes the predominant form of estrogen in 
the body following completion of menopause. 
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Appendix 
 
Table 1. Passage 14 cells Å490, treated with estrogen and no IGF.  Contents of wells is located 
in Table 2 of report. 
 
 1 2 3 4 4 5 
A 0 1.342 1.305 1.103 0.997 0.71 
B 0.69 0.724 0.384 0.482 0.486 0.374 
C 0.565 0.737 0.659 0.647 0.635 0.609 
D 0.868 0.996 0.594 0.932 0.93 0.459 
 AVG 0.94975 0.7355 0.791 0.762 0.538 
 
Table 2. Passage 11 cells Å490, treated with estrogen and no IGF.  Contents of wells is located 
in Table 2 of report. 
 
 1 2 3 4 5 6 
A 0 0.364 1.933 1.253 1.348 1.532 
B 0.976 1.402 1.318 1.452 1.271 1.254 
C 1.654 1.562 1.025 1.175 1.416 1.614 
D 1.43 1.054 1.39 1.238 1.202 1.562 
 AVG 1.0955 1.4165 1.2795 1.30925 1.4905 
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Table 3. Passage 13 cells Å490, treated with estrogen and no IGF. Contents of wells is located in 
Table 2 of report. 
 
 1 2 3 4 5 6 
A 0 1.298 0.766 0.71 0.429 1.142 
B 0.334 0.415 0.496 0.416 0.471 0.419 
C 0.883 0.962 1.349 0.892 1.045 0.762 
D 0.406 0.25 0.884 0.742 0.659 0.324 
 AVG 0.73125 0.87375 0.69 0.651 0.66175 
 
 
Table 4. Passage 10 cells Å490, treated with estrogen and no IGF. Contents  of wells is located 
in Table 3 of report. 
 1 2 3 4 
A 0.445 0.237 0.399 0 
B 0.350 0.445 0.322 0.400 
C 0.205 0.355 0.243 0.224 
Avg 0.278 0.400 0.283 0.312 
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Table 5. Passage 8 cells Å490, treated with estrogen and no IGF. Contents  of wells is located in 
Table 3 of report. 
 1 2 3 4 
A 0.469 0.299 0.448 0 
B 0.181 0.226 0.200 0.188 
C 0.177 0.199 0.176 0.245 
Avg 0.179 0.213 0.188 0.217 
 
Table 6.  Å490 data for cells treated with IGF in addition to estrogen. Omitted data indicates 
position of  well containing only media to serve as a blank. 
 
[M] 
estrogen 
Passage 17 Passage 8 Passage 9 Passage 12 
1x10-7 0.673 0.542 0.822 1.074 
5x10-8 1.128 0.767 0.426 0.882 
2.5x10-8 0.761 0.838 0.44 0.185 
1.25x10-9 0.616 1.013 1.041 0.472 
6.25-9 --- 0.811 0.423 0.948 
0 0.397 0.509 0.817 0.98 
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Table 7.  Protein concentrations obtained from estrogen and IGF treated passage 13 cells in 
preparation for the Bradford assay. 
 
[M] estrogen mg/ml protein 
1x10-7 8.77 
5x10-8 16.91 
2.5x10-8 9.68 
1.25x10-9 15.77 
6.25-9 16.91 
0 12.18 
 
 
